MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today introduced a new cation exchange column line with specialized consumables to simplify and improve the characterization and monitoring of monoclonal antibody (mAb) therapeutics. The new BioResolve™ SCX mAb Columns and Vanguard™ FIT Cartridge technologies, together with a suite of complementary consumables, enable mAb charge-variant analyses as required by the World Health Organization, the U.S. Food and Drug Administration, and the International Conference on Harmonization for confirming the efficacy and safety of biologics and biosimilars within discovery, development, and manufacturing applications.
“With the introduction of these product offerings, we’re taking a holistic approach to mAb analysis and moving it a significant step forward. Scientists now have a complete set of tools for mAb charge variant analyses that will give them a more complete and detailed picture of their mAbs and the relationship between mAb structure and their function,” said Dr. Erin Chambers, Vice President, Chemistry, Waters Corporation. “Our goal is to help streamline analytical workflows and speed up drug candidate development to get needed therapeutics to patients faster.”
BioResolve SCX mAb Columns contain an innovative strong-cation exchanger based on a novel polymeric composition, hydrophilic coating and multi-component surface chemistry all synthesized at Waters chemistry manufacturing facility. The base material consists of three-micron non-porous particles for optimal diffusion kinetics, high pressure capability and compatibility with HPLC, UHPLC and UPLC™ methods.
The columns are also available with a first–of-its-kind Vanguard Fully Integrated Technology (FIT) Cartridge which prevents particulates and other contaminants from being carried onto the column thereby extending its working life and reducing the cost-per-analysis without compromising the quality of the separation. Each batch of material for the BioResolve SCX mAb columns and VanGuard FIT cartridges are specifically quality control-tested with a new and commercially-available mAb charge variant standard derived from the National Institute of Science and Technology Reference Material 8671 (i.e. humanized IgG1κ) to help ensure batch-to-batch consistency of the new offering.
When used with Waters liquid chromatography systems equipped with Auto•Blend™ PLUS technology, scientists can take advantage of pre-configured Empower™ software methods and automatically blend up to four solvents in any combination or proportion and program in pH and ionic strength. This significantly reduces human error and eliminates the task of preparing buffered mobile phases manually. Waters has also specifically formulated new BioResolve SCX pH buffer concentrates with recommended gradient separation conditions for those scientists looking for a “turnkey” solution for mAb charge variant analyses.
The introduction of the new BioResolve SCX mAb Columns and consumables, along with the recent introduction of the Waters BioAccord™ System, reinforce Waters commitment to innovation and to addressing the evolving needs of the biopharmaceutical industry.
Waters BioResolve SCX mAb Columns and consumables are now available worldwide.
For more information on the Waters BioResolve SCX mAb Consumables and Vanguard FIT Cartridges, go to: www.waters.com/bioresolve.
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), the world's leading specialty measurement company, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With approximately 7,000 employees worldwide, Waters operates directly in 31 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.
Waters, Empower, ACQUITY, Auto•Blend, UPLC, BioResolve and Vanguard are trademarks of Waters Corporation.